These results strongly suggest that SKI can inhibit MCP-1 and CCR2 via the p38 MAPK and NFκB signaling pathways, thereby alleviating inflammation and mitigating kidney damage in diabetic nephropathy (Figure 8). Here, CCR2 is linked to diabetic kidney disease.